Yizhou Jiang
0000-0002-6537-9766
Publication & Citation Trends
Publications
129 total
Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study OA
Cited by 16
Semantic Scholar
The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.
Cited by 4
Semantic Scholar
Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice OA
Cited by 6
Semantic Scholar
FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.
Cited by 2
Semantic Scholar
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma PDF
Cited by 147
OpenAlex
Molecular subtypes and precision treatment of triple-negative breast cancer PDF
Cited by 132
OpenAlex
Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity
Cited by 0
Semantic Scholar
miR-613 Suppresses Chemoresistance and Stemness in Triple-Negative Breast Cancer by Targeting FAM83A OA
Cited by 20
Semantic Scholar
Research Topics
CAR-T cell therapy research
(41)
Biosimilars and Bioanalytical Methods
(13)
Lymphoma Diagnosis and Treatment
(11)
Gastric Cancer Management and Outcomes
(11)
Organ Transplantation Techniques and Outcomes
(10)
Affiliations
Université Paris-Sud
Ningbo University
Cliniques Universitaires Saint-Luc
Amgen (United States)
Shanghai Medical College of Fudan University